We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved treatment options. Our efforts are led by late-stage development programs of sparsentan, which is a novel product candidate targeting rare kidney diseases – focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). We are also partnering with leaders in patient advocacy and the National Institutes of Health (NIH) on earlier-stage development work in rare liver diseases. In addition, TVT-058, the first potential disease-modifying therapy for the treatment of classical homocystinuria (HCU), is in Phase 1/2 development.
Today we aim to help patients with our four approved commercial therapies, Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin), and Thiola EC® (tiopronin) delayed-release tablets. We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. We also sponsor diagnostic testing at no cost to qualified patients to help accurately diagnose a variety of disorders.
Because of our patient-centered purpose and recognition that rare disease has no borders, we supported the creation of the Rare Disease Network at Children’s National Rare Disease Institute (CNRDI). The network exists to improve rare disease care in the US and internationally through innovative digital medicine technology and partnerships with rare disease experts.
In our commitment to support caregivers of people living with rare disease, we worked with NORD to establish the Rare Caregiver Respite Program, and with the National Alliance of Caregivers to better understand and help meet the needs of rare caregivers.
We also supported the first-ever Diversity Inclusion Advocacy Fellowship at the EveryLife Foundation for Rare Diseases to increase the representative diversity of patient voices and to engage low income and minority communities in advocacy.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2020 to be approximately $51 million.
On December 9, Travere Therapeutics held a virtual R&D day to review the company’s key pipeline programs. The event featured presentations from external experts and the Travere Therapeutics senior management team.
Watch the recorded webcast >
Eric Dube, Ph.D., Interviewed on Global Genes’ Rarecast Podcast: With a New Identity, Travere Therapeutics Seeks to Find Its True Path
SAN DIEGO, November 30, 2020 – SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in the first quarter of 2021. Read the press release >
November 18, 2020 – Today, the Black Women’s Health Imperative (BWHI) announced the launch of a comprehensive multi-channel campaign entitled RISE for Rare (#riseforrare).
RET153
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
NewsSAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Read the full press release >